Alterity Therapeutics Limited Cash Flow Conversion Efficiency

Latest as of June 2023: -0.222x

Alterity Therapeutics Limited cash flow conversion efficiency. Based on the latest financial reports, Alterity Therapeutics Limited (PBN) has a cash flow conversion efficiency ratio of -0.222x as of June 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-5.06 Million ≈ $-5.91 Million USD) by net assets (€22.81 Million ≈ $26.67 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of Alterity Therapeutics Limited (2014–2025)

Cash flow conversion efficiency of Alterity Therapeutics Limited from 2014 to 2025. This chart illustrates how Alterity Therapeutics Limited's cash flow conversion efficiency has evolved over time, based on yearly financial data. View PBN live share price for real-time trading data and today's change.

Alterity Therapeutics Limited Cash Flow Conversion Ratio Explained

Alterity Therapeutics Limited cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

Alterity Therapeutics Limited Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Alterity Therapeutics Limited ranked by their cash flow conversion efficiency. Also see market value of Alterity Therapeutics Limited for the company's overall valuation and market capitalisation.

Company	Cash Flow Conversion Efficiency
CAG Group AB (publ) ST:CAG	-0.019x
Aditya Birla Money Limited NSE:BIRLAMONEY	0.060x
Duran-Dogan Basim ve Ambalaj Sanayi AS IS:DURDO	0.120x
SYNergy ScienTech Corp TW:6558	0.016x
Complex Micro Interconnection Co. Ltd. TW:6835	-0.011x
Gagasan Nadi Cergas Berhad KLSE:0206	0.242x
DY Corporation KO:013570	0.007x
Gold Terra Resource Corp V:YGT	-0.011x

Annual Cash Flow Conversion Efficiency for Alterity Therapeutics Limited (2014–2025)

The table below shows the annual cash flow conversion efficiency of Alterity Therapeutics Limited from 2014 to 2025. Review financial flexibility index of Alterity Therapeutics Limited to assess the company's free cash flow relative to its total liabilities.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-06-30	€42.40 Million ≈ $49.57 Million	€-11.45 Million ≈ $-13.39 Million	-0.270x	+70.44%
2024-06-30	€13.80 Million ≈ $16.13 Million	€-12.61 Million ≈ $-14.74 Million	-0.914x	-4.02%
2023-06-30	€22.81 Million ≈ $26.67 Million	€-20.04 Million ≈ $-23.42 Million	-0.878x	-152.49%
2022-06-30	€35.47 Million ≈ $41.47 Million	€-12.34 Million ≈ $-14.42 Million	-0.348x	+38.84%
2021-06-30	€30.47 Million ≈ $35.62 Million	€-17.33 Million ≈ $-20.26 Million	-0.569x	+56.88%
2020-06-30	€7.15 Million ≈ $8.36 Million	€-9.43 Million ≈ $-11.03 Million	-1.319x	-56.46%
2019-06-30	€16.55 Million ≈ $19.35 Million	€-13.95 Million ≈ $-16.31 Million	-0.843x	-117.06%
2018-06-30	€16.08 Million ≈ $18.80 Million	€-6.25 Million ≈ $-7.30 Million	-0.388x	-56.86%
2017-06-30	€23.69 Million ≈ $27.70 Million	€-5.87 Million ≈ $-6.86 Million	-0.248x	-4.68%
2016-06-30	€31.37 Million ≈ $36.67 Million	€-7.42 Million ≈ $-8.67 Million	-0.237x	+14.91%
2015-06-30	€39.11 Million ≈ $45.73 Million	€-10.87 Million ≈ $-12.71 Million	-0.278x	+22.62%
2014-06-30	€37.69 Million ≈ $44.06 Million	€-13.54 Million ≈ $-15.83 Million	-0.359x	--

About Alterity Therapeutics Limited

F:PBN Germany Biotechnology

Market Cap

$1.83 Billion

€1.57 Billion EUR

Market Cap Rank

#20686 Global

#1871 in Germany

Share Price

€0.14

Change (1 day)

-1.37%

52-Week Range

€0.00 - €0.41

All Time High

€0.41